Please enable JS

Overview

We are utilizing our MIDAS technology to design novel drugs that we expect to have improved potency, greater selectivity and superior therapeutic index. Our initial drug discovery and development efforts have been focused on a clinically validated metalloenzyme target, fungal CYP51, with broad applications in the treatment of human fungal infections. More recently, we have initiated drug discovery efforts focused on additional metalloenzyme targets relevant to oncology and certain orphan diseases. We believe that our technology is applicable to a broad range of metalloenzyme targets across many therapeutic indications.

VT-1161

VT-1161 is an orally available inhibitor of fungal CYP51 that has shown high potency and selectivity in in vitro studies. The molecule is in Phase 2b clinical testing for the treatment of onychomycosis and recurrent vulvovaginal candidiasis. Read More

VT-1129

VT-1129 is an orally available inhibitor of fungal CYP51 that has shown high potency and selectivity in in vitro studies. The molecule is in Phase 1 clinical testing for the treatment of cryptococcal meningitis. Read More

VT-1598

VT-1598 is an orally available inhibitor of fungal CYP51 that has shown high potency and selectivity in in vitro studies. The molecule is in late-stage preclinical testing for a range of invasive fungal infections, including coccidioidomycosis, also known as Valley Fever. Read More

Other Programs

Utilizing our MIDAS technology, we have developed a number of earlier stage programs addressing fungal, oncology and orphan indications. These programs are in various stages of preclinical testing. Read More